drugset / Trial / NCT02314299

A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration

NCT02314299

Phase 1/2 Completed 20 enrolled Stealth BioTherapeutics Inc.
Non-randomizedOpen-labelTreatment

Summary

This is a Phase 1/2, open-label, dose-escalation clinical study, enrolling 21 subjects in one of the two treatment groups to determine the effects of topical ocular administration of low dose or high dose MTP-131 given twice a day in subjects with Diabetic Macular Edema and Age-Related Macular Degeneration.

Timeline

Start
2014-11
Primary completion
2015-05
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Elamipretide Peptide Topical